Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zymeworks Inc.

ZYME ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$30.81

▲ +3.98%

Market Cap $2.17B · Vol 335.08K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: 23.92

Market Cap

$2.17B

Mid Cap

Div Yield

N/A

EPS Growth

+196.24%

YoY

RSI (14)

70.90

Momentum

Beta

1.27

vs Market

52W High

$31.49

2.16% below

52W Low

$16.61

85.49% above

Volume

335.08K

Avg 273.04K

P/B

7.37

Price-to-book

ROE

-26.72%

Return on equity

Free Float

92.72%

Public shares

Shariah Compliance8 STANDARDS

✗ Zymeworks Inc. (ZYME) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZYME pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.28%

+19.46%

+30.88%

+28.97%

YTD

+17.01%

+87.18%

+322.63%

+39.66%

Financials & Valuation

TTM · Annual

Total Revenue	$105.97M
Net Income	$-81,130,000.00
Revenue Growth (YoY)	-90.58%
Gross Margin	100.00%
Operating Margin	-87.34%
Net Profit Margin	-76.56%
ROE	-26.72%
ROA · ROIC	-19.70% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	23.92
PEG Ratio	N/A
P/S	18.74
P/B	7.37
P/FCF	N/A
EPS Growth	+196.24%
Outstanding Shares	70.48M

Technical Indicators

50-Day SMA	$27.46
200-Day SMA	$25.41
RSI (14)	70.90
Beta	1.27
52-Week High	$31.49
52-Week Low	$16.61

Volume Today	335.08K
Avg Daily Volume (30D)	273.04K
Relative Volume	1.23x
Volatility (10D)	49.89
Volatility (30D)	47.01
Free Float	92.72%

Analyst Consensus

BUY

Current Price $30.81

Mean Target $42.42

52W Low$16.61 52W High$31.49

Current

Target

$16.61 $31.49

Current Analyst target

+37.67% upside potential · 12 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG019XSYC98

ISINUS98985Y1082

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.27% ARGX.BR argenx SE +4.66% ARGX argenx SE +3.78% GMAB.CO Genmab A/S +3.80% GMAB Genmab A/S +4.05%

Company Profile

Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.